


# Amaxa® Human Monocyte Nucleofector® Kit


## For Human Monocytes


Human monocytes freshly isolated from blood samples or buffy coats.


Note This protocol only gives an outline for the handling and the Nucleofection® of human monocytes. Please refer to more detailed preparation and cultivation protocols before starting the experiments


Example for Nucleofection® of CD14+ monocytes with pmaxGFP® Vector












Human monocytes freshly enriched from peripheral blood mononuclear cells (PBMC) were transfected with 1 µg pmaxGFP® Vector using the Human Monocyte Nucleofector® Kit. 22 hours post Nucleofection®, the cells were stained with an antibody directed against CD14 and analyzed by flow cytometry. PBMC were gated according to forward/side scatter (A). Dead cells were excluded by propidium iodide staining and gating (B). CD14 positive cells were identified by staining with CD14-antibody (C). Expression of maxGFP® Reporter Protein is shown after Nucleofection® without (D) and with plasmid DNA (E).



Transfection efficiency of primary human monocytes 24 hours post Nucleofection®. Cells were transfected using Nucleofector® Program Y-001 and 1  $\mu$ g of pmaxGFP® Vector. Cell viability is usually around 70% [%PI negative monocytes] after 24 hours.

## **Product Description**

| Cat. No.   | VPA-1007                         |  |
|--|----------------------------------|--|
| Size (reactions)                                 | 25                               |  |
| Human Monocyte Nucleofector® Solution            | 2.25 ml (2.05 ml + 10% overfill) |  |
| Supplement                                       | 0.5 ml (0.45 ml + 10% overfill)  |  |
| pmaxGFP® Vector (0.5 μg/μl in 10 mM Tris pH 8.0) | 30 µg                            |  |
| Certified cuvettes                               | 25                               |  |
| Plastic pipettes                                 | 25                               |  |

Storage and stability

Store Nucleofector® Solution, Supplement and pmaxGFP® Vector at 4°C. For long-term storage, pmaxGFP® Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector® Supplement is added to the Nucleofector® Solution it is stable for three months at 4°C.

## Optimized Protocol for Human Monocytes

Note

## **Required Material**

Please make sure that the entire supplement is added to the Nucleofector® Solution. The ratio of Nucleofector® Solution to supplement is 4.5:1. For a single reaction use 82 µl of Nucleofector® Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector® Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260: A280 ratio should be at least 1.8
- 24-well culture dish or culture system of your choice
- Culture medium: Clonetics® Lymphocyte Growth Media-3 LGM-3® for serum-free culture [Lonza, Cat. No. CC-3211] or BioWhittaker® IMDM media for addition of 10% serum [Lonza, Cat.No. BE12-722F]
- For isolation: FicoII-Paque™ Plus [GE Healthcare; Cat. No. 17-1440-03]; PBS containing 0.5% [w/v] BSA [PBS/BSA]
- For enrichment: We recommend using the Rosette Sep™ Isolation Kit for human monocytes [Stem Cell Technologies, 1.1 Cat.No. 15028]. Please note: It is also possible to use the Monocyte Isolation Kit II [Miltenyi Biotec, Cat.No. 130-091-153] to purify the monocytes Appropriate number of cells  $[3 \times 10^6 - 1 \times 10^7]$  cells per sample
- Prewarm appropriate volume of culture medium to 37°C (1.5 ml per sample)
- Appropriate number of cells  $(3 \times 10^6 1 \times 10^7)$  cells per sample; lower or higher cell numbers may influence transfection results)

#### 1. Pre Nucleofection®

Note

Transfection results may be donor - dependent.

#### Enrichment of monocytes from buffy coats

- 1.1 Centrifuge one buffy coat (~60 ml) in two 50 ml tubes at 1200xg for 20 minutes at RT (brake off)
- 1.2 Remove most of the serum in the upper layer
- 1.3 Transfer the interphases (PBMC) together with traces of serum and erythrocytes (~15 ml) into two fresh 50 ml tubes
- 1.4 Add 1000  $\mu$ l cold Rosette-Cocktail (4°C) to each PBMC-Mix and vortex
- 1.5 Incubate 20 minutes at RT
- 1.6 Dilute 15 ml of the PBMC-Mix with 15 ml PBS/BSA and mix gently
- 1.7 Prepare two 50 ml tubes with 15 ml Ficoll-Paque™ and place 30 ml of the diluted PBMC-Mix as a layer on top of the Ficoll-Paque™
- 1.8 Centrifuge at 1200xg for 20 minutes at RT with brake off
- 1.9 Collect the interphase and transfer it to a fresh 50 ml tube on ice
- 1.10 Wash the enriched cells 2x with ice-cold PBS/BSA
- 1.11 Resuspend cells in 5 ml PBS/BSA

Note If you want to enrich monocytes from whole blood please refer to the Rosette Sep® Procedure for Human Monocyte Enrichment Cocktail (www.stemcell.com).

## **Optimized Protocol for Human Monocytes**

- 1.12 Add PBS/BSA to 50 ml mark, mix and centrifuge at 350xg for 10 minutes at 4°C. Remove the supernatant carefully
- 1.13 Resuspend the cell pellet in 25 ml of PBS/BSA and centrifuge at 160xg for 15 minutes at 4°C. Remove the supernatant carefully

## 2. Nucleofection®

## One Nucleofection® Sample contains

 $3 \times 10^6 - 1 \times 10^7$  cells

 $1-5~\mu g$  plasmid DNA (in  $1-5~\mu l$  H $_2$ 0 or TE) or  $2~\mu g$  pmaxGFP® Vector or 30-300~nM siRNA (3-30~pmol/sample)

100 µl Human Monocyte Nucleofector® Solution

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 24-well plates by filling appropriate number of wells with 1.5 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified 37°C/5% CO<sub>2</sub> incubator
- 2.3 Count the cells and determine cell density
- 2.4 Centrifuge the required numbers of cells (3 x  $10^6 1$  x  $10^7$  cells per sample) at 200xg for 10 12 minutes at room temperature. Discard supernatant completely so that no residual PBS/BSA covers the cell pellet
- 2.5 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector® Solution per sample. Avoid storing the cell suspension longer than 15 minutes in Human Monocyte Nucleofector® Solution, as this reduces cell viability and gene transfer efficiency
- 2.6 Combine 100  $\mu$ l of cell suspension with 1 5  $\mu$ g DNA, 2  $\mu$ g pmaxGFP® Vector or 30 300 nM siRNA (3 30 pmol/sample) or other substrates
- 2.7 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.8 Select the appropriate Nucleofector® Program Y-001 (Y-01 for Nucleofector® | Device)
- 2.9 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program
- 2.10 Take the cuvette out of the holder once the program is finished
- 2.11 Add  $\sim$  500  $\mu$ l of the pre-equilibrated supplemented culture medium to the cuvette and **gently** transfer the sample into the 24-well plate (final volume of 1.5 ml media per well). Use the supplied pipettes and avoid repeated aspiration of the sample

### 3. Post Nucleofection®

3.1 Incubate the cells in humidified  $37^{\circ}$ C/5%  $CO_2$  incubator until analysis. Gene expression is often detectable after only 4 - 8 hours. If this is not the case, the incubation period may be prolonged to 24 or 48 hours

## Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

#### For more technical assistance, contact our Scientific Support Team:

 USA / Canada
 Europe and Rest of World

 Phone:
 800 521 0390 (toll-free)
 Phone: +49 221 99199 400

 Fax:
 301 845 8338
 Fax: +49 221 99199 499

#### Lonza Cologne AG 50829 Cologne, Germany

Please note that the Amaxa® Nucleofector® Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection, maxGFP, LGM-3, Clonetics and Biowhittaker are either registered trademarks or trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

FicoII-Paque is a trademark of GE Healthcare.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne AG. All rights reserved DPA-1008 08/09